Privia Health Group (PRVA) Set to Announce Earnings on Thursday

Privia Health Group (NASDAQ:PRVA) is set to release its earnings data before the market opens on Thursday, May 9th. Analysts expect Privia Health Group to post earnings of $0.05 per share for the quarter. Privia Health Group has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Privia Health Group (NASDAQ:PRVA) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. On average, analysts expect Privia Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Privia Health Group Stock Performance

Shares of PRVA opened at $19.08 on Tuesday. The stock has a market capitalization of $2.26 billion, a PE ratio of 100.42, a P/E/G ratio of 2.56 and a beta of 0.81. Privia Health Group has a 1 year low of $17.54 and a 1 year high of $30.15. The company’s 50-day simple moving average is $19.62 and its 200-day simple moving average is $21.09.

Insider Transactions at Privia Health Group

In other news, CFO David Mountcastle sold 2,320 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $42,734.40. Following the sale, the chief financial officer now owns 259,959 shares of the company’s stock, valued at approximately $4,788,444.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO David Mountcastle sold 2,320 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total value of $42,734.40. Following the sale, the chief financial officer now owns 259,959 shares of the company’s stock, valued at approximately $4,788,444.78. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas Bartrum sold 2,252 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total value of $41,481.84. Following the completion of the sale, the executive vice president now directly owns 103,862 shares in the company, valued at approximately $1,913,138.04. The disclosure for this sale can be found here. Insiders have sold 31,783 shares of company stock valued at $582,886 in the last quarter. 14.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PRVA. TD Cowen reduced their price target on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Truist Financial reduced their target price on shares of Privia Health Group from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Jefferies Financial Group assumed coverage on shares of Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 target price on the stock. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th. Finally, Evercore ISI dropped their price target on shares of Privia Health Group from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.58.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.